Matthias Alder - Sep 20, 2022 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role
Chief Operating Officer, Director
Signature
/s/ Jason Minio, Attorney-in-Fact
Stock symbol
GANX
Transactions as of
Sep 20, 2022
Transactions value $
$0
Form type
4
Date filed
9/22/2022, 04:06 PM
Previous filing
Jul 19, 2022
Next filing
Mar 27, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GANX Employee Stock Option (right to buy) Award $0 +60.9K $0.00 60.9K Sep 20, 2022 Common Stock 60.9K $3.50 Direct F1
transaction GANX Restricted Stock Units Award $0 +10.2K $0.00 10.2K Sep 20, 2022 Common Stock 10.2K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option shall vest 25% on September 20, 2023 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F3 The RSUs shall vest 25% on September 20, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.